MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

The latest financial statement is for the year ending 2025-12-31.

Cash Flow Overview

Free Cash flow
$748.7M

Unit: Million (M) dollars (except for numbers of shares and EPS)
Cash Flow
2025-12-31
Net income
478.6
Stock-based compensation
217.9
Charges associated with convertible senior notes
0
Impairment charges associated with leased properties
0.7
Depreciation
26
Accretion of discount on available-for-sale debt securities, net
12.7
Amortization of acquired intangible assets
4.1
Changes in fair values of equity investments
-4
Deferred tax assets
165.4
Non-cash lease expense
26.8
Other
0.7
Accounts receivable
210.5
Inventory
15.3
Accounts payable and accrued liabilities
160.2
Income tax assets and liabilities
-18.8
Other assets and liabilities, net
44.4
Cash flows from operating activities
782.7
Purchases of available-for-sale debt securities
1,319.8
Sales and maturities of available-for-sale debt securities
1,089.4
Purchases of equity investments
0
Capital expenditures
34
Cash flows from investing activities
-264.4
Issuances of common stock under benefit plans
129.4
Repurchases of common stock
167.7
Payments to settle convertible senior notes
0
Cash flows from financing activities
-38.3
Effect of exchange rate changes on cash and cash equivalents
0
Change in cash and cash equivalents and restricted cash
480
Cash and cash equivalents at beginning of period
241
Cash and cash equivalents at end of period
721
Unit: Million (M) dollars

Time Plot

Show the time plot by selecting a row from the table.

NEUROCRINE BIOSCIENCES INC (NBIX)

NEUROCRINE BIOSCIENCES INC (NBIX)